<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chan SL</submitter><funding>Cancer Research UK</funding><funding>Medical Research Council</funding><pagination>167-181</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7206612</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>9(2)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The aim of current study was to (1) construct and validate a novel hepatocellular carcinoma (HCC)-specific inflammatory index; (2) compare the performances of the Integrated Liver Inflammatory Score (ILIS) to existing 4 inflammatory indices in HCC; (3) explore the association between the inflammatory indices and systemic/intratumoral inflammatory markers.&lt;h4>Methods&lt;/h4>Two cohorts from Hong Kong (HK; &lt;i>n&lt;/i> = 1,315) and Newcastle (&lt;i>n&lt;/i> = 574) were studied. A novel index was constructed from the HK training set (&lt;i>n&lt;/i> = 627). The index was constructed from the training set by combing independent prognostic circulating parameters, followed by validating in the validation set of HK cohort (&lt;i>n&lt;/i> = 688) and the Newcastle cohort. Its prognostic performance was compared to 4 inflammatory indices, namely, the neutrophil to lymphocyte ratio, platelet-to-lymphocyte ratio, prognostic nutrition index, and systemic immune-inflammation index, were compared in the HK cohort. Circulating cytokines and intratumoral gene expression were analyzed in a subset of patients with available samples and correlated with the inflammatory indices.&lt;h4>Results&lt;/h4>In the training set of the HK cohort, the ILIS, was generated: -0.057 × albumin (g/L) + 0.978 × log (Bilirubin, µmol/L) + 1.341 × log (alkaline phosphatase, IU/L) + 0.086 × Neutrophil (10&lt;sup>9&lt;/sup>/L) + 0.301 × log (alpha-fetoprotein, µg/L). With cutoff of 2.60 and 3.87, the ILIS could categorize patients into 3 risk groups in the both validation cohorts. ILIS outperforms other inflammatory indices and remains an independent prognosticator for overall survival after adjustment with Barcelona Clinic Liver Cancer (hazard ratio 31.90, &lt;i>p&lt;/i> &lt; 0.001). The ILIS had the best prognostic performances as compared to other inflammatory indices. In exploratory analyses, the ILIS correlated with circulating inflammatory cytokines (e.g., IL-8) but not with any intratumoral inflammatory gene expression.&lt;h4>Conclusions&lt;/h4>ILIS is an HCC-specific prognostic index built on 5 readily available blood parameters. Its versatility is validated both Eastern and Western population of HCC. The score is correlated with levels of circulating cytokines.</pubmed_abstract><journal>Liver cancer</journal><pubmed_title>Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma.</pubmed_title><pmcid>PMC7206612</pmcid><funding_grant_id>MC_PC_14101</funding_grant_id><funding_grant_id>26813</funding_grant_id><pubmed_authors>Chong CC</pubmed_authors><pubmed_authors>Chan SL</pubmed_authors><pubmed_authors>Reeves HL</pubmed_authors><pubmed_authors>Chan KA</pubmed_authors><pubmed_authors>Chan AW</pubmed_authors><pubmed_authors>Wong LL</pubmed_authors><pubmed_authors>Liu PH</pubmed_authors><pubmed_authors>Wong GL</pubmed_authors><pubmed_authors>Chow C</pubmed_authors><pubmed_authors>To KF</pubmed_authors><pubmed_authors>Yip TC</pubmed_authors><pubmed_authors>Wong VW</pubmed_authors><pubmed_authors>Tong JH</pubmed_authors><pubmed_authors>Chu CM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma.</name><description>&lt;h4>Background&lt;/h4>The aim of current study was to (1) construct and validate a novel hepatocellular carcinoma (HCC)-specific inflammatory index; (2) compare the performances of the Integrated Liver Inflammatory Score (ILIS) to existing 4 inflammatory indices in HCC; (3) explore the association between the inflammatory indices and systemic/intratumoral inflammatory markers.&lt;h4>Methods&lt;/h4>Two cohorts from Hong Kong (HK; &lt;i>n&lt;/i> = 1,315) and Newcastle (&lt;i>n&lt;/i> = 574) were studied. A novel index was constructed from the HK training set (&lt;i>n&lt;/i> = 627). The index was constructed from the training set by combing independent prognostic circulating parameters, followed by validating in the validation set of HK cohort (&lt;i>n&lt;/i> = 688) and the Newcastle cohort. Its prognostic performance was compared to 4 inflammatory indices, namely, the neutrophil to lymphocyte ratio, platelet-to-lymphocyte ratio, prognostic nutrition index, and systemic immune-inflammation index, were compared in the HK cohort. Circulating cytokines and intratumoral gene expression were analyzed in a subset of patients with available samples and correlated with the inflammatory indices.&lt;h4>Results&lt;/h4>In the training set of the HK cohort, the ILIS, was generated: -0.057 × albumin (g/L) + 0.978 × log (Bilirubin, µmol/L) + 1.341 × log (alkaline phosphatase, IU/L) + 0.086 × Neutrophil (10&lt;sup>9&lt;/sup>/L) + 0.301 × log (alpha-fetoprotein, µg/L). With cutoff of 2.60 and 3.87, the ILIS could categorize patients into 3 risk groups in the both validation cohorts. ILIS outperforms other inflammatory indices and remains an independent prognosticator for overall survival after adjustment with Barcelona Clinic Liver Cancer (hazard ratio 31.90, &lt;i>p&lt;/i> &lt; 0.001). The ILIS had the best prognostic performances as compared to other inflammatory indices. In exploratory analyses, the ILIS correlated with circulating inflammatory cytokines (e.g., IL-8) but not with any intratumoral inflammatory gene expression.&lt;h4>Conclusions&lt;/h4>ILIS is an HCC-specific prognostic index built on 5 readily available blood parameters. Its versatility is validated both Eastern and Western population of HCC. The score is correlated with levels of circulating cytokines.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Apr</publication><modification>2025-05-29T21:15:32.718Z</modification><creation>2025-05-29T21:15:32.718Z</creation></dates><accession>S-EPMC7206612</accession><cross_references><pubmed>32399431</pubmed><doi>10.1159/000504252</doi></cross_references></HashMap>